CTLA4 and neoplasm: CTLA-4 inhibitors, such as ipilimumab, enhance T-cell activity and promote T-cell proliferation and cytokine secretion by blocking the binding of CTLA-4 to B7 molecules, thereby activating the immune system’s attack on tumor cells (34).